{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:47:52Z","timestamp":1773820072388,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"DOI":"10.7759\/cureus.105417","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:45:21Z","timestamp":1773816321000},"source":"Crossref","is-referenced-by-count":0,"title":["Highly Aggressive Relapsing Course of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease Requiring Intensive Care Unit Treatment and Quadruple Immunotherapy"],"prefix":"10.7759","author":[{"given":"Deepak","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiebke","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian P","family":"Kamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Diem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000813","article-title":"Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases","volume":"33","author":"Mader S","year":"2020","unstructured":"Mader S, K\u00fcmpfel T, Meinl E. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases. Curr Opin Neurol. 2020, 33:362-71. 10.1097\/WCO.0000000000000813","journal-title":"Curr Opin Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70169","article-title":"Reply to letter: \"real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay\"","volume":"12","author":"Said Y","year":"2025","unstructured":"Said Y, Flanagan EP, Sotirchos ES. Reply to letter: \"real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay\". Ann Clin Transl Neurol. 2025, 12:2378-9. 10.1002\/acn3.70169","journal-title":"Ann Clin Transl Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52310","article-title":"Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay","volume":"12","author":"Said Y","year":"2025","unstructured":"Said Y, Filippatou A, Tran C, et al.. Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay. Ann Clin Transl Neurol. 2025, 12:556-64. 10.1002\/acn3.52310","journal-title":"Ann Clin Transl Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10024-0","article-title":"Cell-based assays for the detection of MOG antibodies: a comparative study","volume":"267","author":"Gastaldi M","year":"2020","unstructured":"Gastaldi M, Scaranzin S, Jarius S, et al.. Cell-based assays for the detection of MOG antibodies: a comparative study. J Neurol. 2020, 267:3555-64. 10.1007\/s00415-020-10024-0","journal-title":"J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1252650","article-title":"Comparison of live and fixed cell-based assay performance: implications for the diagnosis of MOGAD in a low-middle income country","volume":"14","author":"Pandit L","year":"2023","unstructured":"Pandit L, D'Cunha A, Malli C, Sudhir A. Comparison of live and fixed cell-based assay performance: implications for the diagnosis of MOGAD in a low-middle income country. Front Immunol. 2023, 14:1252650. 10.3389\/fimmu.2023.1252650","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104571","article-title":"Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"72","author":"Chang X","year":"2023","unstructured":"Chang X, Zhang J, Li S, Wu P, Wang R, Zhang C, Wu Y. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease. Mult Scler Relat Disord. 2023, 72:7. 10.1016\/j.msard.2023.104571","journal-title":"Mult Scler Relat Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2024.0276","article-title":"Phenotype of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease in children","volume":"21","author":"Han JY","year":"2025","unstructured":"Han JY, Kim SY, Kim W, et al.. Phenotype of relapsing myelin oligodendrocyte glycoprotein antibody-associated disease in children. J Clin Neurol. 2025, 21:65-73. 10.3988\/jcn.2024.0276","journal-title":"J Clin Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3934\/Neuroscience.2025008","article-title":"Interleukin-6 targeting antibodies for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of current literature","volume":"12","author":"Ganesh SR","year":"2025","unstructured":"Ganesh SR, Yedidia O, Pandey K, Infortuna C, Madiraju C, Thomas FP, Battaglia F. Interleukin-6 targeting antibodies for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of current literature. AIMS Neurosci. 2025, 12:113-39. 10.3934\/Neuroscience.2025008","journal-title":"AIMS Neurosci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein M","year":"2022","unstructured":"Ringelstein M, Ayzenberg I, Lindenblatt G, et al.. Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2022, 9:11. 10.1212\/NXI.0000000000001100","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo A","year":"2019","unstructured":"Cobo-Calvo A, Sep\u00falveda M, Rollot F, et al.. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation. 2019, 16:134. 10.1186\/s12974-019-1525-1","journal-title":"J Neuroinflammation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan S","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, et al.. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018, 89:127-37. 10.1136\/jnnp-2017-316880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0338-z","article-title":"A comprehensive next generation sequencing-based virome assessment in brain tissue suggests no major virus - tumor association","volume":"4","author":"Strong MJ","year":"2016","unstructured":"Strong MJ, Blanchard E 4th, Lin Z, et al.. A comprehensive next generation sequencing-based virome assessment in brain tissue suggests no major virus - tumor association. Acta Neuropathol Commun. 2016, 4:71. 10.1186\/s40478-016-0338-z","journal-title":"Acta Neuropathol Commun"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007096","article-title":"A multicenter comparison of MOG-IgG cell-based assays","volume":"92","author":"Waters PJ","year":"2019","unstructured":"Waters PJ, Komorowski L, Woodhall M, et al.. A multicenter comparison of MOG-IgG cell-based assays. Neurology. 2019, 92:e1250-5. 10.1212\/WNL.0000000000007096","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1192644","article-title":"High level of agreement in a fixed vs. live cell-based assay for antibodies to myelin oligodendrocyte glycoprotein in a real-world clinical laboratory setting","volume":"14","author":"Smith TL","year":"2023","unstructured":"Smith TL, Haven TR, Zuromski LM, Luong K, Clardy SL, Peterson LK. High level of agreement in a fixed vs. live cell-based assay for antibodies to myelin oligodendrocyte glycoprotein in a real-world clinical laboratory setting. Front Neurol. 2023, 14:4. 10.3389\/fneur.2023.1192644","journal-title":"Front Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi E","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, et al.. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022, 13:885218. 10.3389\/fneur.2022.885218","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell B","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, et al.. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023, 22:268-82. 10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106548","article-title":"MOGAD treatment outcomes and relapse characteristics: real world experience from a low-middle income country","volume":"100","author":"Jain K","year":"2025","unstructured":"Jain K, Dhamija K, Holla VV, Thennarasu K, Bhat M, Mahadevan A, Netravathi M. MOGAD treatment outcomes and relapse characteristics: real world experience from a low-middle income country. Mult Scler Relat Disord. 2025, 100:106548. 10.1016\/j.msard.2025.106548","journal-title":"Mult Scler Relat Disord"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106631","article-title":"Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onset","volume":"102","author":"Tisavipat N","year":"2025","unstructured":"Tisavipat N, Wilf-Yarkoni A, Al-Ani A, et al.. Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onset. Mult Scler Relat Disord. 2025, 102:106631. 10.1016\/j.msard.2025.106631","journal-title":"Mult Scler Relat Disord"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241226830","article-title":"Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"30","author":"Bilodeau PA","year":"2024","unstructured":"Bilodeau PA, Vishnevetsky A, Molazadeh N, et al.. Effectiveness of immunotherapies in relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler. 2024, 30:357-68. 10.1177\/13524585241226830","journal-title":"Mult Scler"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1509143","article-title":"Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review","volume":"16","author":"Zhang J","year":"2025","unstructured":"Zhang J, Hu M, Wang C, Guo S. Successful sequential therapy with rituximab and telitacicept in refractory Anti-NMDA receptor encephalitis and MOG-associated demyelination: a case report and literature review. Front Immunol. 2025, 16:3. 10.3389\/fimmu.2025.1509143","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103310","article-title":"Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder","volume":"56","author":"Thakolwiboon S","year":"2021","unstructured":"Thakolwiboon S, Zhao-Fleming H, Karukote A, Mao-Draayer Y, Flanagan EP, Avila M. Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder. Mult Scler Relat Disord. 2021, 56:103310. 10.1016\/j.msard.2021.103310","journal-title":"Mult Scler Relat Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/461235-highly-aggressive-relapsing-course-of-myelin-oligodendrocyte-glycoprotein-mog-antibody-associated-disease-requiring-intensive-care-unit-treatment-and-quadruple-immunotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:45:21Z","timestamp":1773816321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/461235-highly-aggressive-relapsing-course-of-myelin-oligodendrocyte-glycoprotein-mog-antibody-associated-disease-requiring-intensive-care-unit-treatment-and-quadruple-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.105417","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}